1. Home
  2. ABUS vs HIPO Comparison

ABUS vs HIPO Comparison

Compare ABUS & HIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABUS
  • HIPO
  • Stock Information
  • Founded
  • ABUS 2005
  • HIPO 2015
  • Country
  • ABUS United States
  • HIPO United States
  • Employees
  • ABUS N/A
  • HIPO N/A
  • Industry
  • ABUS Biotechnology: Pharmaceutical Preparations
  • HIPO Property-Casualty Insurers
  • Sector
  • ABUS Health Care
  • HIPO Finance
  • Exchange
  • ABUS Nasdaq
  • HIPO Nasdaq
  • Market Cap
  • ABUS 611.0M
  • HIPO 694.3M
  • IPO Year
  • ABUS N/A
  • HIPO N/A
  • Fundamental
  • Price
  • ABUS $3.22
  • HIPO $26.86
  • Analyst Decision
  • ABUS Strong Buy
  • HIPO Strong Buy
  • Analyst Count
  • ABUS 4
  • HIPO 4
  • Target Price
  • ABUS $5.50
  • HIPO $31.50
  • AVG Volume (30 Days)
  • ABUS 774.3K
  • HIPO 222.0K
  • Earning Date
  • ABUS 08-04-2025
  • HIPO 08-06-2025
  • Dividend Yield
  • ABUS N/A
  • HIPO N/A
  • EPS Growth
  • ABUS N/A
  • HIPO N/A
  • EPS
  • ABUS N/A
  • HIPO N/A
  • Revenue
  • ABUS $6,403,000.00
  • HIPO $397,300,000.00
  • Revenue This Year
  • ABUS $3.35
  • HIPO $29.23
  • Revenue Next Year
  • ABUS N/A
  • HIPO $21.57
  • P/E Ratio
  • ABUS N/A
  • HIPO N/A
  • Revenue Growth
  • ABUS N/A
  • HIPO 55.80
  • 52 Week Low
  • ABUS $2.71
  • HIPO $14.58
  • 52 Week High
  • ABUS $4.73
  • HIPO $35.44
  • Technical
  • Relative Strength Index (RSI)
  • ABUS 48.90
  • HIPO 49.91
  • Support Level
  • ABUS $3.08
  • HIPO $26.54
  • Resistance Level
  • ABUS $3.30
  • HIPO $27.41
  • Average True Range (ATR)
  • ABUS 0.10
  • HIPO 0.89
  • MACD
  • ABUS 0.01
  • HIPO -0.10
  • Stochastic Oscillator
  • ABUS 50.00
  • HIPO 26.27

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About HIPO Hippo Holdings Inc.

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

Share on Social Networks: